Studies on the anti-cancer mechanisms of Bortezomib by proteomic techniques
碩士 === 臺北醫學大學 === 醫學科學研究所 === 96 === The proteasome is an abundant multi-enzyme complex that provides the main roles for selective degradation of intracellular unfolding proteins in eukaryotic cells. Bortezomib (PS-341) is a proteasome inhibitor which first approved by FDA to enter clinical trails i...
Main Authors: | Yung-Hsin Hsine, 謝永信 |
---|---|
Other Authors: | 梁有志 |
Format: | Others |
Language: | zh-TW |
Published: |
2008
|
Online Access: | http://ndltd.ncl.edu.tw/handle/37021058183723060400 |
Similar Items
-
Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells
by: Shu Wang, et al.
Published: (2017-04-01) -
Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib
by: Wang Xia, et al.
Published: (2009-07-01) -
Data for a proteomic analysis of p53-independent induction of apoptosis by bortezomib
by: Azmi Yerlikaya, et al.
Published: (2014-12-01) -
Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy
by: Shota Yamamoto, et al.
Published: (2021-01-01) -
Molecular mechanisms of bortezomib resistant adenocarcinoma cells.
by: Erika Suzuki, et al.
Published: (2011-01-01)